Positions

Overview

  • Boni Elewski, M.D., an international leader in fungal and psoriasis research and dermatological clinical trials, was named the new chair of the University of Alabama at Birmingham Department of Dermatology in 2016.

    Elewski had been a professor of Dermatology at UAB for the past 17 years. She holds the James E. Elder M.D. Endowed Professorship for Graduate Education.

    Elewski is an international leader in fungal and psoriasis research and dermatological clinical trials. She’s been conducting clinical trials through her entire career and has received 85 clinical trial study grants to pursue therapies for many dermatologic conditions. She’s authored more than 300 publications and served in numerous national societies and organizations, including as president of the American Academy of Dermatology from 2004-2005.

    A part of the School of Medicine since its inception in 1945, the UAB Department of Dermatology has been one of the top academic departments of dermatology in the United States for over 70 years and includes 18 faculty, 13 residents and two fellows. The department provides comprehensive dermatological patient care, offering sophisticated services in the diagnosis and treatment of skin disease, and is a national center for the management of complicated skin disorders.

    An Ohio native, Elewski began her career at the Ohio State University College of Medicine, where she earned her medical degree before beginning an internship in internal medicine and residency in dermatology the University of North Carolina Memorial Hospital. She held faculty positions at the Northeastern Ohio University College of Medicine and the Case Western Reserve School of Medicine before joining the UAB faculty in 1999.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy 2019
    2019 Itch: an under-recognized problem in psoriasis 2019
    2019 Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials 2019
    2019 Treatment of Tinea Capitis 2019
    2019 Isolated Nail Dystrophy: An Unlikely Presentation of Metastatic Renal Cell Carcinoma 2019
    2019 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities 2019
    2019 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics 2019
    2019 Lichen Planopilaris in the Setting of Hair Sunscreen Spray 2019
    2019 Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial 2019
    2019 Association of psoriasis/psoriatic arthritis with irritable bowel disease influences management strategy 2019
    2019 Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor 2019
    2019 Successful treatment of dermatophytomas in 19 patients using efinaconazole 10% solution 2019
    2018 Single-Center, Prospective, Blinded Study Comparing the Efficacy and Compatibility of Efinaconazole 10% Solution in Treating Onychomycosis with and without Concurrent Nail Polish Use 2018
    2018 Subungual Space: The Next Frontier 2018
    2018 Ungual Horn 2018
    2018 Is Biotin Safe for Dermatology Patients? 2018
    2018 A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis 2018
    2018 Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials 2018
    2018 Human polyomavirus-7–associated eruption successfully treated with acitretin 2018
    2018 Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum 2018
    2018 Efinaconazole 10% topical solution: Case review of onychomycosis patients who were completely cured at Week 24 2018
    2018 Injection site necrosis and ulceration following vaccination in an adult patient 2018
    2018 Safety of secukinumab in hepatitis B virus 2018
    2018 Is severity of disease a prognostic factor for cure following treatment of onychomycosis? 2018
    2018 Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial 2018
    2017 Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab 2017
    2017 Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis 2017
    2017 Cutaneous plasmacytosis resembling pityriasis rosea in a 66-year-old white woman: A rare disease presenting in an unusual patient demographic 2017
    2016 Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review 2016
    2016 Topical treatment for onychomycosis: Is it more effective than the clinical data suggests? 2016
    2016 Response to A financial perspective on the topical treatment of onychomycosis 2016
    2016 To the Editor 2016
    2016 Onychomycosis: Does cure equate to treatment success? 2016
    2016 Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole. 2016
    2016 Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: Results of two phase 3, randomized, placebo-controlled clinical trials 2016
    2016 Onychomycosis: Strategies to minimize recurrence 2016
    2016 Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis 2016
    2016 Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review 2016
    2016 Secukinumab (AIN-457) for the treatment of Psoriasis 2016
    2016 Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence 2016
    2015 Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables 2015
    2015 Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables. 2015
    2015 Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis 2015
    2015 Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution 2015
    2015 A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea 2015
    2015 Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies 2015
    2015 Risk factors and comorbidities for onychomycosis: Implications for treatment with topical therapy 2015
    2015 Tanning accelerators: Prevalence, predictors of use, and adverse effects 2015
    2015 The ABCDEF rule: Combining the 'ABCDE rule' and the "ugly duckling sign" in an effort to improve patient self-screening examinations 2015
    2015 Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials 2015
    2014 A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis 2014
    2014 Erratum: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies(Journal of the American Academy of Dermatology (2013) 68 (600-8)) 2014
    2014 Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space 2014
    2014 Econazole nitrate foam 1% for the treatment of tinea pedis: Results from two double-blind, vehicle-controlled, phase 3 clinical trials 2014
    2014 Secukinumab in plaque psoriasis - Results of two phase 3 trials 2014
    2014 Tavaborole for the treatment of onychomycosis 2014
    2014 The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: A pooled analysis of two phase 3 randomized trials 2014
    2014 Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life 2014
    2013 Azelaic acid foam 15% in the treatment of papulopustular rosacea: A randomized, double-blind, vehicle-Controlled study 2013
    2013 Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser 2013
    2013 Item-level psychometric properties for a new patient-reported psoriasis symptom diary 2013
    2013 Efinaconazole 10% solution: A new topical antifungal therapy for onychomycosis 2013
    2013 Current and emerging options in the treatment of onychomycosis 2013
    2013 Diagnosis, clinical implications, and complications of onychomycosis 2013
    2013 Nail findings board review 2013
    2013 Onychomycosis information for patients. 2013
    2013 Program spotlight: The University of Alabama at Birmingham Department of Dermatology Residency Training Program 2013
    2013 Promoting and maintaining or restoring healthy nails: Practical recommendations for clinicians and patients 2013
    2013 Resident Rounds. Part III B: tumor necrosis factor-α antagonists and alopecia areata: a class-wide adverse effect. 2013
    2013 The epidemiology, etiology, and pathophysiology of onychomycosis 2013
    2013 Tumor necrosis factor-α antagonists and alopecia areata: A class-wide adverse effect 2013
    2013 Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: Results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs 2013
    2013 Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies 2013
    2013 New side effect of TNF-α inhibitors: Morphea 2013
    2013 Onchomycosis: an overview. 2013
    2013 Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy 2013
    2013 To the editor 2013
    2012 Cosmetic aspects of nail products and services 2012
    2012 Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors 2012
    2012 A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis 2012
    2011 A new classification system for grading the severity of onychomycosis: Onychomycosis severity index 2011
    2011 Recent updates in oral terbinafine: Its use in onychomycosis and tinea capitis in the US 2011
    2011 Tinea capitis caused by dermatophytes: A 15-year retrospective study from a Mississippi dermatology clinic 2011
    2011 An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis 2011
    2011 Tinea capitis in Birmingham: Survey of elementary school students 2011
    2011 Interest in cosmetic improvement as a marker for tanning behavior: A survey of 1602 respondents 2011
    2011 Rosacea - Global diversity and optimized outcome: Proposed international consensus from the Rosacea international expert group 2011
    2011 Systemic drugs in patients with skin diseases 2011
    2010 Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial 2010
    2010 Wong type dermatomyositis: 20th case reported 2010
    2010 Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study 2010
    2010 Letters to the editor 2010
    2010 Naftifine, a topical allylamine. 2010
    2010 Cyclosporine and psoriasis: 2008 National Psoriasis Foundation* Consensus Conference 2010
    2010 Optimizing topical therapies for treating psoriasis: a consensus conference. 2010
    2010 Top-accessed article: White superficial onychomycosis 2010
    2009 Onychomycosis and diabetes 2009
    2009 Safe and effective treatment of seborrheic dermatitis 2009
    2009 Lack of classic histology should not prevent diagnosis of necrolytic acral erythema 2009
    2009 Results of a National Rosacea Patient Survey: Common issues that concern rosacea sufferers 2009
    2009 An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. 2009
    2009 Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis 2009
    2009 Rosacea: A review of current topical, systemic and light based therapies 2009
    2008 The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis 2008
    2008 Infliximab for the treatment of severe pustular psoriasis: 6 Years later 2008
    2008 Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials* 2008
    2008 The prevalence of acne in adults 20 years and older 2008
    2007 Reply 2007
    2007 Onychomycosis: Diagnosis and definition of cure 2007
    2007 Advances in Topical and Systemic Antifungals 2007
    2007 New opportunities in preventative dermatology: How far should we go? 2007
    2007 Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model 2007
    2007 A new gel formulation of miconazole nitrate 2% for the treatment of chronic intertrigo 2007
    2007 A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. 2007
    2007 Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis 2007
    2007 Letter to the editor 2007
    2007 Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%. 2007
    2007 Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris 2007
    2006 Azelaic acid gel 15%: Clinical versatility in the treatment of rosacea 2006
    2006 Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. 2006
    2006 Azelaic acid 15% gel for treatment of rosacea 2006
    2006 A clinical overview of azelaic acid 2006
    2006 Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy 2006
    2006 Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomized, double-blind comparison 2006
    2006 Alefacept in the treatment of psoriatic nail disease: a proof of concept study. 2006
    2006 Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. 2006
    2006 Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial 2006
    2005 A bipartite interaction between Pseudomonas aeruginosa and fungi in onychomycosis [5] 2005
    2005 A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis 2005
    2005 Clinical diagnosis of common scalp disorders. 2005
    2005 Modification of the nail psoriasis severity index [8] (multiple letters) 2005
    2004 Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea [2] (multiple letters) 2004
    2004 Bioterrorism 2004
    2004 The use of 40% urea cream in the treatment of moccasin tinea pedis 2004
    2004 Onychotillomania: 2 Case reports 2004
    2004 Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002 2004
    2004 Guidelines of care for atopic dermatitis 2004
    2003 A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular Rosacea: Results of a Randomized Trial 2003
    2003 Tinea capitis in adult women masquerading as bacterial pyoderma 2003
    2003 Tinea capitis in adult women masquerading as bacterial pyoderma. 2003
    2003 Tinea capitis in Cleveland: Survey of elementary school students 2003
    2003 Tinea corporis, tinea cruris, tinea nigra, and piedra 2003
    2002 Cutaneous anthrax management algorithm 2002
    2002 Infliximab for the treatment of severe pustular psoriasis [1] 2002
    2002 Office practice-based confirmation of onychomycosis: A US nationwide prospective survey 2002
    2002 Extrafacial and generalized granulomatous periorificial dermatitis 2002
    2002 The diagnosis and treatment of nail disorders: Systemic antifungal therapy 2002
    2002 Cutaneous fungal infections in the elderly 2002
    2002 Reactivity to trichophytin antigen in patients with onychomycosis: Effect of terbinafine 2002
    2001 Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris 2001
    2001 Guidelines of care for liposuction 2001
    2001 Itraconazole pulse therapy is effective and well-tolerated for the treatment of mycotic skin disease 2001
    2001 The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. 2001
    2001 Tinea capitis of childhood: Incidence and pathogenetic role, of Trichophyton tonsurans in Central Europe [4] (multiple letters) [4] 2001
    2000 A novel treatment for acne vulgaris and rosacea [2] 2000
    2000 Drug-induced photosensitivity with antimycotics 2000
    2000 The diagnosis of nail fungus infection revisited 2000
    2000 A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns 2000
    2000 Antifungal drug interactions 2000
    2000 Erratum: Tinea capitis: A current perspective (Journal of the American Academy of Dermatology (January 2000) 42 (1-20)) 2000
    2000 New developments in cutaneous fungal infections 2000
    2000 Onychomycosis: Treatment, quality of life, and economic issues 2000
    2000 Sex-based professional societies are by no means obsolete - Yet [1] 2000
    2000 Tinea capitis : a current perspective 2000
    2000 Tinea capitis: A current perspective 2000
    2000 Tinea capitis: a current perspective. 2000
    1999 Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail 1999
    1999 Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. 1999
    1999 Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine 1999
    1999 Asthma induced by allergy to Trichophyton rubrum 1999
    1999 A full 'cure' for onychomycosis is not always possible [4] (multiple letters) 1999
    1999 British journal of dermatology: Introduction 1999
    1999 Novel treatment strategies for superficial mycoses: Introduction 1999
    1999 Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method 1999
    1999 Safety of itraconazole pulse therapy for onychomycosis. An update. 1999
    1999 Treatment of tinea capitis: Beyond griseofulvin 1999
    1999 Treatment of tinea pedis when bacterial presence is suspected: A review of the literature 1999
    1999 Update on superficial fungal infections. Introduction. 1999
    1998 Onychomycosis: Pathogenesis, diagnosis, and management 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail 1998
    1998 Once-weekly fluconazole in the treatment of onychomycosis: Introduction 1998
    1998 Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail 1998
    1998 Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. 1998
    1998 Once-weekly fluconazole in the treatment of onychomycosis: introduction. 1998
    1998 Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. 1998
    1998 Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. 1998
    1998 Tinea capitis: Fluconazole in trichophyton tonsurans infection 1998
    1997 A historical perspective on onychomycosis 1997
    1997 Tinea capitis treatment 1997
    1997 Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. 1997
    1997 Trichophyton rubrum Onychomycosis in a 17-Year-Old Girl 1997
    1997 Large-scale epidemiological study of the causal agents of onychomycosis: Mycological findings from the multicenter onychomycosis study of terbinafine [7] 1997
    1997 Prevalence of onychomycosis in patients attending a dermatology clinic in Northeastern Ohio for other conditions [3] 1997
    1997 Fungal infections in HIV-infected patients 1997
    1997 Treatment of tinea capitis with itraconazole 1997
    1997 Proposed Guidelines for Speakers Discussing Medications and Other Products 1997
    1997 Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis 1997
    1997 Superficial fungal infections: Errors to avoid in diagnosis and treatment 1997
    1997 A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: A multicentre study 1997
    1997 A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the tingemail 1997
    1997 Bacterial infection in a patient with onychomycosis 1997
    1997 Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [4] (multiple letters) 1997
    1997 One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial 1997
    1997 Onychomycosis in children: Prevalence and treatment strategies 1997
    1997 Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial 1997
    1997 The effect of toenail onychomycosis on patient quality of life 1997
    1997 The use of itraconazole in the treatment of superficial and systemic fungal infections 1997
    1997 Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream 1997
    1996 Diagnostic techniques for confirming onychomycosis 1996
    1996 Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study 1996
    1996 Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis 1996
    1996 Restructuring dermatology education at Cleveland medical centers affiliated with Case Western Reserve University 1996
    1996 Diagnostic techniques for confirming onychomycosis. 1996
    1996 Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. 1996
    1996 Widespread papules and nodules in a Ugandan man with acquired immunodeficiency syndrome 1996
    1996 Cutaneous mycoses in children 1996
    1996 Surgical pearl: Nail micronizer 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/Outcomes Committee. American Academy of Dermatology. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. 1996
    1996 Surgical pearl: nail micronizer. 1996
    1996 A U.S. epidemiologic survey of superficial fungal diseases 1996
    1996 Clinical pearl: Diagnostic procedures for tinea capitis 1996
    1996 Cutaneous Lesions Provide a Clue to Mysterious Pulmonary Process 1996
    1996 Cutaneous antifungal therapy in AIDS: Summary of an International Summit 1996
    1996 Cutaneous lesions provide a clue to mysterious pulmonary process. Pulmonary and cutaneous North American blastomycosis infection. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Mucocutaneous candidiasis 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Onychomycosis 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Piedra 1996
    1996 International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11-13, 1994 1996
    1996 Nondermatophyte causes of onychomycosis and superficial mycoses. 1996
    1996 Onychomycosis caused by Scytalidium dimidiatum 1996
    1996 Systemic antifungal drugs and drug interactions [2] 1996
    1996 Thrombocytopenia caused by fluconazole [4] 1996
    1996 Tinea capitis 1996
    1996 Update on the management of onychomycosis: Highlights on the Third Annual International Summit on Cutaneous Antifungal Therapy 1996
    1995 Antifungal agents 1995
    1995 Bonsai tree: Risk factor for disseminated sporotrichosis 1995
    1995 Candida as a nail pathogen in healthy patients. 1995
    1995 Clinical Pearl: Systemic antifungal drugs and drug interactions 1995
    1995 Clinical pearl: Diagnosis of onychomycosis 1995
    1995 Cost of therapy for dermatophyte infections 1995
    1995 Cutaneous involvement with Cryptococcus neoformans in AIDS [4] 1995
    1995 Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections 1995
    1995 Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole 1995
    1995 Reply 1995
    1995 Thrombocytopenia caused by fluconazole therapy 1995
    1995 Trends in the Management of Cutaneous Fungal Infections 1995
    1995 Zosteriform zygomycosis 1995
    1994 Short-duration therapy for superficial tinea infections [1] 1994
    1994 Cutaneous involvement with Cryptococcus neoformans in AIDS 1994
    1994 Dermatophytes as opportunistic pathogens 1994
    1994 Introduction: International Summit on Cutaneous Antifungal Therapy 1994
    1994 Tinea capitis: Itraconazole in Trichophyton tonsurans infection 1994
    1993 Therapy of sporotrichosis 1993
    1993 Malignant fibrous histiocytoma resembling mycetoma. 1993
    1993 Mechanisms of action of systemic antifungal agents. 1993
    1993 Clinical Pearl: Proximal white subungual onychomycosis in AIDS 1993
    1993 Malignant fibrous histiocytoma resembling mycetoma 1993
    1993 Mechanisms of action of systemic antifungal agents 1993
    1992 Cutaneous blastomycosis 1992
    1992 Pyostomatitis vegetans and primary sclerosing cholangitis: Markers of inflammatory bowel disease 1992
    1991 Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature. 1991
    1991 Childhood epidermolysis bullosa acquisita: Report of three cases and review of literature 1991
    1991 Hendersonula toruloidea and Scytalidium hyalinum: Review and Update 1991
    1991 Pigmented postacne osteoma cutis in a patient treated with minocycline: Report and review of the literature 1991
    1991 Rosacea‐Like Lesions due to Familial Mycobacterium avium‐intracellulare Infection 1991
    1990 Does Pityrosporum Ovale Have a Role in Psoriasis? 1990
    1989 The superficial mycoses and the dermatophytes. 1989
    1989 The superficial mycoses and the dermatophytes 1989
    1986 Reply to Dr. Holdiness 1986
    1985 Eruptive lesions and malignancy. 1985
    1985 Eruptive Lesions and Malignancy 1985
    1983 In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline 1983

    Chapter

    Year Title Altmetric
    2018 Systemic antifungals.  425-450. 2018
    2014 Tinea Barbae.  67-70. 2014
    2005 Onychomycosis.  123-131. 2005

    Research Overview

  • Dr. Boni Elewski’s research is aimed at developing new and innovative methods to diagnose and manage cutaneous fungal infections caused by dermatophyte fungi, as well as to establish their prevalence in certain populations. For example, she has determined that these common skin infections are increasing in prevalence at alarming rates and are particularly common in those immunocompromised by disease (HIV) or therapy (transplant recipients). Finding that tinea capitis (scalp ringworm) occurs in about 14% of children in Ohio, a four-fold increase in the past decade, Dr. Elewski is currently determining the prevalence of tinea capitis in Alabama and looking for links with other conditions, such as asthma and attention deficit disorder, that have also increased in prevalence in recent years. She also found that onychomycosis (nail fungus) occurs in 13% of the US population, a five fold increase over the last 50 years. Although effective antimycotic agents are available for treatment of these conditions, they continue to remain a diagnostic dilemma, and there is no simple diagnostic tool. Consequently, Dr. Elewski co-founded a dermatomycology laboratory at UAB to further study diagnosis and identification of these common infections. Dr. Elewski has also investigated the treatment of cutaneous fungal infections. Her work includes pivotal clinical studies on their management in children and adults. Additionally, Dr. Elewski found that immunologic response to fungal antigens or proteins is a predictor of treatment outcome. Her research is done through clinical trials, and the newly created UAB Fungal Reference Laboratory.
  • Principal Investigator On

  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2024
  • Private Grant  awarded by LILLY USA, LLC 2019 - 2024
  • Private Grant  awarded by ANAPTYSBIO INC. 2019 - 2024
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by INCYTE CORPORATION 2019 - 2024
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2019 - 2024
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CARA THERAPEUTICS, INC. 2019 - 2024
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2019 - 2024
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY 2019 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2019 - 2024
  • Private Grant  awarded by LEO PHARMA 2019 - 2024
  • Private Grant  awarded by VALEANT PHARMACEUTICALS NORTH AMERICA LLC 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by MENLO THERAPEUTICS INC 2018 - 2023
  • Private Grant  awarded by Procter & Gamble Company 2018 - 2023
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2023
  • Private Grant  awarded by ANAPTYSBIO INC. 2018 - 2023
  • Private Grant  awarded by LILLY USA, LLC 2018 - 2023
  • Private Grant  awarded by MENLO THERAPEUTICS INC 2018 - 2023
  • Private Grant  awarded by VANDA PHARMACEUTICALS INC. 2018 - 2023
  • Private Grant  awarded by INFLARX GMBH 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2023
  • Private Grant  awarded by LEO PHARMA 2018 - 2023
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by ELI LILLY AND COMPANY 2017 - 2022
  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2022
  • Private Grant  awarded by ALLERGAN SALES, LLC 2017 - 2022
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2016 - 2021
  • Private Grant  awarded by JANSSEN PHARMACEUTICALS PRODUCTS LP 2008 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Private Grant  awarded by NOVAN, INC. 2016 - 2021
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2015 - 2020
  • Private Grant  awarded by Janssen Biotech, Inc. 2019 - 2020
  • Private Grant  awarded by ABBVIE INC 2019 - 2020
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2020
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2019
  • Private Grant  awarded by Janssen Biotech, Inc. 2018 - 2019
  • Private Grant  awarded by ABBVIE INC 2018 - 2019
  • Private Grant  awarded by DUSA PHARMACEUTICALS, INC. 2015 - 2019
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2019
  • Private Grant  awarded by Janssen 2015 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2018
  • Private Grant  awarded by Janssen Biotech, Inc. 2017 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2012 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2018
  • Private Grant  awarded by ABBVIE INC 2016 - 2017
  • Private Grant  awarded by Janssen Biotech, Inc. 2016 - 2017
  • Private Grant  awarded by VIAMET PHARMACEUTICALS, INC. - NEW 2015 - 2017
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2017
  • Private Grant  awarded by Janssen 2015 - 2016
  • Private Grant  awarded by Janssen Biotech, Inc. 2015 - 2016
  • Private Grant  awarded by ABBVIE INC 2015 - 2016
  • Fellowship Sponsorship/Grant  awarded by HAMAD MEDICAL CORPORATION 2011 - 2016
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2016
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Private Grant  awarded by MEIJI SEIKA PHARMA CO LTD - NEW 2014 - 2015
  • Private Grant  awarded by XENOPORT, INC. 2014 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by Janssen Biotech, Inc. 2014 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by Janssen Biotech, Inc. 2013 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by INTENDIS, INC. 2012 - 2014
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2013 - 2014
  • Private Grant  awarded by VIAMET PHARMACEUTICALS, INC. - NEW 2013 - 2014
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by ASUBIO PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by CELGENE CORPORATION 2012 - 2014
  • Private Grant  awarded by NOVEN PHARMACEUTICAL, INC. 2011 - 2013
  • Private Grant  awarded by GALDERMA RESEARCH AND DEVELOPMENT, INC. 2010 - 2013
  • Private Grant  awarded by Centocor 2010 - 2013
  • Private Grant  awarded by Genentech 2006 - 2013
  • Private Grant  awarded by Centocor 2004 - 2013
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2013
  • Private Grant  awarded by Centocor 2012 - 2013
  • Private Grant  awarded by Bayer HealthCare 2013
  • Private Grant  awarded by Janssen 2013
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Private Grant  awarded by GALDERMA RESEARCH AND DEVELOPMENT, INC. 2012 - 2013
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2013
  • Private Grant  awarded by JANSSEN PHARMACEUTICALS PRODUCTS LP 2012 - 2013
  • Private Grant  awarded by ANACOR PHARMACEUTICALS 2011 - 2013
  • Private Grant  awarded by CUTERA, INC. 2011 - 2013
  • Private Grant  awarded by AMGEN, INC. 2006 - 2013
  • Private Grant  awarded by MARUHO CO, LTD 2011 - 2013
  • Private Grant  awarded by Centocor 2006 - 2013
  • Private Grant  awarded by QUINNOVA 2011 - 2012
  • Private Grant  awarded by NITRIC BIOTHERAPEUTICS, INC. 2010 - 2012
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2008 - 2012
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2011 - 2012
  • Private Grant  awarded by ABBOTT LABORATORIES 2011 - 2012
  • Private Grant  awarded by Centocor 2011 - 2012
  • Private Grant  awarded by DOW PHARMACEUTICAL SCIENCES 2010 - 2011
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2011
  • Private Grant  awarded by ABBOTT LABORATORIES 2008 - 2011
  • Private Grant  awarded by AMGEN, INC. 2007 - 2011
  • Private Grant  awarded by AMGEN, INC. 2009 - 2011
  • Dermatology Research Fellowship 2010-2011  awarded by National Psoriasis Foundation 2010 - 2011
  • Private Grant  awarded by Centocor 2010 - 2011
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2010 - 2011
  • Private Grant  awarded by INTENDIS, INC. 2010 - 2011
  • Private Grant  awarded by DEPOMED, INC. 2008 - 2010
  • Private Grant  awarded by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC 2008 - 2010
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2008 - 2010
  • Investigator On

  • Private Grant  awarded by AMGEN, INC. 2010 - 2012
  • Education And Training

  • University of North Carolina Hospital, Residency 1982
  • Full Name

  • Boni Elewski